DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide ( IDegLira ) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin-Reference-Cited by-同舟云学术

DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide ( IDegLira ) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin

Published:2021-08-31 Issue:12 Volume:23 Page:2687-2696
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Pei Yu¹,Agner Bue R.²,Luo Bin³,Dong Xiaolin⁴,Li Dongmei⁵,Liu Jun⁶,Liu Lei⁷,Liu Ming⁸,Lu Yibing⁹,Nishida Tomoyuki¹⁰,Xu Xiangjin¹¹,Mu Yiming¹^ORCID

Affiliation:

1. Department of Endocrinology Chinese People's Liberation Army General Hospital Beijing China

2. Bispebjerg Hospital Copenhagen Denmark

3. Novo Nordisk China Pharmaceuticals Beijing China

4. Department of Endocrinology Jinan Central Hospital, Shandong University Jinan China

5. Department of Endocrinology Inner Mongolia People's Hospital Hohhot China

6. Department of Endocrinology Fifth People's Hospital of Shanghai Shanghai China

7. Novo Nordisk A/S Søborg Denmark

8. Department of Endocrinology and Metabolism Tianjin Medical University General Hospital Tianjin China

9. Department of Endocrinology The Second Affiliated Hospital of Nanjing Medical University Nanjing China

10. Novo Nordisk Pharma Ltd Tokyo Japan

11. Department of Endocrinology Fuzhou General Hospital Fuzhou China

Funder

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14522

Reference23 articles.

1. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

2. Diabetes in China: mapping the road ahead

3. Comparison of postprandial glycaemia in Asians and Caucasians

4. Effects of Different Proportion of Carbohydrate in Breakfast on Postprandial Glucose Excursion in Normal Glucose Tolerance and Impaired Glucose Regulation Subjects

5. Epidemiology of diabetes and diabetic complications in China

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of fixed‐ratio combination insulin degludec/liraglutide in type 2 diabetes: A systematic review and meta‐analysis of randomised controlled trials;Diabetes/Metabolism Research and Reviews;2023-11-27

2. IDegLira for type 2 diabetes: a systematic review and meta-analysis;Endocrine;2023-09-28

3. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients;Diabetology & Metabolic Syndrome;2023-08-19

4. Distinct hypoglycemic effect of different formulations of a fixed ratio of basal insulin plus glucagon-like peptide-1 receptor agonist in a patient with pancreatic diabetes;Diabetology International;2023-04-10

5. Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China;Frontiers in Pharmacology;2022-11-18